

# Press Release

**ProStrakan Group plc**

## **ProStrakan Signs In-Licensing Agreement for Tabphyn®**

**23 March 2006** – ProStrakan Group plc, the European specialty pharmaceutical company, today announces that it has agreed to acquire the UK rights to Tabphyn®, a treatment of benign prostatic hyperplasia (BPH – enlargement of the prostate), from Genus Pharmaceuticals Limited, the UK subsidiary of the German generic pharmaceuticals company, Stada Arzneimittel AG. Financial terms of the transaction have not been disclosed.

Under the terms of the ten year agreement, ProStrakan will gain the exclusive rights to market and distribute Tabphyn in the UK. Genus will supply the finished product to ProStrakan and will permit use of the trademark Tabphyn by ProStrakan throughout the term of the agreement.

In 2005, the BPH market in the UK was worth £96.5m (Source: BPI MAT December 2005), and the largest product in the sector was Flomax (Tamsulosin), marketed by Astellas with sales of £52.8m. In September 2005, Astellas launched a new BPH product, Flomaxtra XL, and subsequently withdrew Flomax in November. The withdrawal of Flomax has left an opportunity for ProStrakan to promote Tabphyn, a branded generic version of Flomax, at a lower cost to Flomaxtra XL and parallel imported Flomax. ProStrakan's UK sales force is expected to commence marketing Tabphyn from the beginning of April.

Commenting on today's agreement, Wilson Totten, Chief Executive of ProStrakan, said:

"There is strong demand from doctors and primary care trusts in the UK for Tamsulosin and the withdrawal of Flomax has created a gap in the market. This is an excellent tactical opportunity for ProStrakan to acquire a product with near-term revenues and cash generation which will contribute to our path to profitability. It is also a good example of our ability to move swiftly when situations like this arise and leverage our business development and sales and marketing capabilities."

### ***Enquiries:***

#### **ProStrakan**

Wilson Totten, Chief Executive Officer  
Adrian Gardner, Chief Financial Officer  
David Watt, Corp Comms

Tel: 01896 664000  
Tel: 01896 664000  
Tel: 01896 664103

#### **Financial Dynamics**

David Yates / Sarah Macleod

Tel: 020 7831 3113

## **Notes to Editors**

### **About Benign Prostatic Hyperplasia (BPH)**

BPH is the most common benign neoplasm (non cancerous enlargement of the prostate gland) in men, and has a high prevalence that increases with age. The increase in size of the prostate inside its capsule exerts pressure on the urethra, which passes through the capsule, resulting in obstruction to urine flow.

Half of all men have BPH identifiable histologically at age 60 years, and by 85 years the prevalence is about 90%. In the USA about 25% of men will be treated for BPH by age 80, and over 300,000 surgical procedures are performed each year for BPH (mostly transurethral resection of the prostate, TURP). This makes TURP the second most common surgical procedure, second only to cataract surgery - at a cost estimated at \$2 billion per year.

### **ProStrakan**

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company's therapeutic focus is on oncology supportive care, bone diseases, women's health and issues relating to the ageing male. Headquartered in Scotland, the Company's R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are principally handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan floated on the London Stock Exchange in June 2005.

[www.prostrakan.com](http://www.prostrakan.com)